Correcting Postprandial Hyperglycemia in Zucker Diabetic Fatty Rats With an SGLT2 Inhibitor Restores Glucose Effectiveness in the Liver and Reduces Insulin Resistance in Skeletal Muscle
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Ten-week-old Zucker diabetic fatty (ZDF) rats at an early stage of diabetes embody metabolic characteristics of obese human patients with type 2 diabetes, such as severe insulin and glucose intolerance in muscle and the liver, excessive postprandial excursion of plasma glucose and insulin, and a loss of metabolic flexibility with decreased lipid oxidation. Metabolic flexibility and glucose flux were examined in ZDF rats during fasting and near-normal postprandial insulinemia and glycemia after correcting excessive postprandial hyperglycemia using treatment with a sodium–glucose cotransporter 2 inhibitor (SGLT2-I) for 7 days. Preprandial lipid oxidation was normalized, and with fasting, endogenous glucose production (EGP) increased by 30% and endogenous glucose disposal (E-Rd) decreased by 40%. During a postprandial hyperglycemic-hyperinsulinemic clamp after SGLT2-I treatment, E-Rd increased by normalizing glucose effectiveness to suppress EGP and stimulate hepatic glucose uptake; activation of glucokinase was restored and insulin action was improved, stimulating muscle glucose uptake in association with decreased intracellular triglyceride content. In conclusion, SGLT2-I treatment improves impaired glucose effectiveness in the liver and insulin sensitivity in muscle by eliminating glucotoxicity, which reinstates metabolic flexibility with restored preprandial lipid oxidation and postprandial glucose flux in ZDF rats.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 1×
“Merovic et al. (13) and Ferrannini et al. (14) reported that SGLT2-I treatment improves whole-body insulin resistance in patients with T2D.”
BackgroundEctopic Fat in Insulin Resistance, Dyslipidemia, and Cardiometabolic Disease
Shulman, G. I. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1011035 · Cited by 1,126 · cited 1×
“Increased diacylglycerol increases membrane protein kinase C isozyme protein or kinase activity, and impairs insulin signaling (33).”
BackgroundPostprandial Hyperglycemia and Diabetes Complications
Ceriello, A. (2005) · Diabetes · doi:10.2337/diabetes.54.1.1 · Cited by 945
Groop, L. C., Bonadonna, R. C., DelPrato, S., Ratheiser, K., Zyck, K., Ferrannini, E., & DeFronzo, R. A. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114142 · Cited by 812
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Insulin Resistance and Hyperinsulinemia
Shanik, M. H., Xu, Y., Škrha, J., Dankner, R., Zick, Y., & Roth, J. (2008) · Diabetes Care · doi:10.2337/dc08-s264 · Cited by 791
Mitrakou, A., Kelley, D., Mokan, M., Veneman, T., Pangburn, T., Reilly, J., & Gerich, J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201023260104 · Cited by 595
Befroy, D. E., Petersen, K. F., Dufour, S., Mason, G. F., de Graaf, R. A., Rothman, D. L., & Shulman, G. I. (2007) · Diabetes · doi:10.2337/db06-0783 · Cited by 453 · cited 1×
“The combination of increased intracellular lipids and a low oxidative capacity are key features in the development of muscular insulin resistance in obese patients with T2D (4,29,30).”
BackgroundMolecular Physiology of Mammalian Glucokinase
Iynedjian, P. B. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8322-9 · Cited by 365
M USCLE T RIGLYCERIDE AND I NSULIN R ESISTANCE
Kelley, D. E., Goodpaster, B. H., & Storlien, L. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.010402.102912 · Cited by 364
Chibalin, A. V., Leng, Y., Vieira, E., Krook, A., Björnholm, M., Long, Y. C., Kotova, O., Zhong, Z., Sakane, F., Steiler, T., et al. (2008) · Cell · doi:10.1016/j.cell.2007.12.035 · Cited by 232
Considine, R. V., Nyce, M. R., Allen, L. E., Morales, L. M., Triester, S., Serrano, J., Colberg, J., Lanza-Jacoby, S., & Caro, J. F. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118001 · Cited by 141 · cited 1×
“(35) reported that normalization of circulating glucose using phlorizin in 10to 12-week-old ZDF rats did not result in an improvement of insulin receptor phosphorylation nor a reduction in increased membrane protein kinase C isozyme protein or kinase activity.”
BackgroundGalgani, J. E., Heilbronn, L. K., Azuma, K., Kelley, D. E., Albu, J. B., Pi-Sunyer, X., Smith, S. R., Ravussin, E., & and the Look AHEAD Adipose Research Group (2008) · Diabetes · doi:10.2337/db08-0043 · Cited by 133 · cited 1×
“It has been reported that impaired metabolic switching is an intrinsic property of skeletal muscle, with lowered fasting lipid oxidation (49,50) and decreased glucose disposal rate related to defective glucose transport (51).”
BackgroundBasu, A., Dalla Man, C., Basu, R., Toffolo, G., Cobelli, C., & Rizza, R. A. (2009) · Diabetes Care · doi:10.2337/dc08-1826 · Cited by 129 · cited 1×
“While the abnormal excursion of postprandial hyperglycemia in T2D results from decreased glucose effectiveness and insulin action to stimulate glucose disposal and suppress EGP (5–8), glucose disposal and suppression of EGP during the postprandial state in T2D are near normal (9).”
BackgroundImpaired skeletal muscle substrate oxidation in glucose-intolerant men improves after weight loss
Corpeleijn, E., Mensink, M., Kooi, M. E., Roekaerts, P. M. H. J., Saris, W. H. M., & Blaak, E. E. (2008) · Obesity · doi:10.1038/oby.2008.24 · Cited by 104 · cited 1×
“It has been reported that impaired metabolic switching is an intrinsic property of skeletal muscle, with lowered fasting lipid oxidation (49,50) and decreased glucose disposal rate related to defective glucose transport (51).”
BackgroundIs hepatic glucose production increased in type 2 diabetes mellitus?
Beck-Nielsen, H., Hother-Nielsen, O., & Staehr, P. (2002) · Current Diabetes Reports · doi:10.1007/s11892-002-0088-0 · Cited by 35
Cited by
Kahl, S., Gancheva, S., Straßburger, K., Herder, C., Machann, J., Katsuyama, H., Kabisch, S., Henkel, E., Kopf, S., Lagerpusch, M., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0641 · Cited by 360
Coelho, F. D. S., Borges‐Canha, M., von Hafe, M., Neves, J. S., Vale, C., Leite, A. R., Carvalho, D., & Leite‐Moreira, A. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3413 · Cited by 61
Mechanisms of aerobic exercise impairment in diabetes: a narrative review
Wahl, M. P., Scalzo, R. L., Regensteiner, J. G., & Reusch, J. E. B. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00181 · Cited by 44
Inaba, Y., Hashiuchi, E., Watanabe, H., Kimura, K., Sato, M., Kobayashi, M., Matsumoto, M., Kitamura, T., Kasuga, M., & Inoue, H. (2019) · Endocrinology · doi:10.1210/en.2019-00422 · Cited by 18
Metadata
- Authors
- O’Brien, T. P., Jenkins, E. C., Estes, S. K., Castaneda, A. V., Ueta, K., Farmer, T. D., Puglisi, A. E., Swift, L. L., Printz, R. L., & Shiota, M.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2017-02-28
- Volume
- 66
- Issue
- 5
- Pages
- 1172-1184
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2594630750
- Cited by
- 48
- References
- 16
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.